Neurological complications after thoracic endovascular aortic repair. Does the left subclavian artery coverage without revascularization increase the risk of neurological complications in patients after thoracic endovascular aortic repair?

Dariusz Janczak¹, Agnieszka Ziomek¹,², Jakub Kobecki², Maciej Malinowski¹, Kornel Pomańczuk²,³ and Mariusz Chabowski²,³*

Abstract

Introduction: One of the most severe complications after TEVAR is ischemic stroke and spinal cord ischemia (SCI) resulting in severe disability. These complications can be fatal up to 30% of cases, so it is very important to define risk factors associated with the occurrence of such events. The aim of this study was to define the causes and risk factors associated with the occurrence of neurological complications in patients after TEVAR.

Materials and methods: We performed a retrospective analysis of 51 patients undergoing TEVAR in the Department of Vascular Surgery of Military Teaching Hospital in Wroclaw between 2014 and 2017. In 18 patients LSA coverage was managed without revascularization (35.29%), and in 33 patients LSA remained uncovered (64.71%).

Results: We did not find any statistically significant difference in the incidence of stroke and spinal cord ischemia in patients with covered and uncovered LSA (stroke \( p = 0.37 \), SCI \( p = 0.58 \)). In the group of patients with covered and uncovered LSA, we did not find any significant differences in the incidence of additional comorbidities such as obesity, ischemic heart disease, hypertension or previous stroke.

Conclusions: There is no difference in stroke and SCI occurrence between patients with covered and uncovered LSA. Although there are many studies analysing the risk of such complications, there is no specific consensus regarding the treatment of LSA coverage. Randomised clinical trials on a large group of patients are still needed.

Keywords: Thoracic endovascular aortic repair (TEVAR), Left subclavian artery (LSA), Cerebrovascular accident (CVA), Stroke, Spinal cord ischemia (SCI)

* Correspondence: mariusz.chabowski@gmail.com

¹Department of Surgery, 4th Military Teaching Hospital, 5 Weigla street, 50-981, Wroclaw, Poland
²Division of Surgical Specialties, Department of Clinical Nursing, Faculty of Health Science, Wroclaw Medical University, 5 Bartla Street, 51-618, Wroclaw, Poland

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Over the last 20 years, the treatment of thoracic aortic conditions has been completely revolutionized by introducing thoracic endovascular aortic repair (TEVAR). Endovascular treatment is associated with reduced mortality and shorter hospital stay compared to open repair [1, 2]. Moreover, such treatment is also more widely accepted by the patients themselves. One of the most severe complications of TEVAR is ischemic stroke and spinal cord ischemia (SCI). The cause of spinal cord ischemia and lower limb paresis is wide coverage of the aorta wall with stentgraft, which closes the arteries that are supplying blood to the spinal cord. Although the risk of SCI and stroke is considered to be lower than in open surgery, it is still as high as 2.5–5% [3]. Neurological complications can be fatal in up to 30% and are associated with long-term disability and handicap, which generates high costs. Therefore, it is very important to define the risk factors associated with such complications in order to prevent them as effectively as possible. Although there is no strong evidence on this subject, it is believed that one of the main risk factors for neurological complications is coverage of the left subclavian artery without revascularization. Some papers argue the opposite, that covering LSA without revascularization does not increase the incidence of neurological complications.

The aim of our work was to define the causes and risk factors associated with neurological complications in patients after TEVAR.

Materials and methods
The records of 51 patients undergoing TEVAR between 2014 and 2017 were retrospectively analysed. Landing zone 0 and 1 was an exclusion criterion. Ischemic stroke was defined as any new loss of neurological functions of vascular ethiology lasting more than 24 h. TIA was defined as any new loss of neurological function of vascular ethiology lasting less than 24 h. Spinal cord ischemia (SCI) was defined as a permanent reduction or complete loss of neurological functions in the limbs. Each patient had thoracic and abdominal angiography before and three months after the surgery. Demographics and comorbidities of the patients are reported in Table 1. The mean age of the patient was 66.37 years. Most of the patients were male (n = 34, 66.67%). 38 patients (74.58%) were hypertensive, 34 (66.67%) patients had a BMI above 25, and almost half of the population was burdened with tobacco use (n = 24, 47.05%). Additionally in 13 cases (25.49%) thoracic aneurysm coexisted with an abdominal aneurysm.

The indication for TEVAR was a thoracic aortic aneurysm (n = 25, 49%) or acute type B aortic dissection (n = 26, 51%). Two patients were operated due to thoracic aortic aneurysm rupture. The vast majority of patients were admitted and operated in urgent mode (n = 34, 66.67%). The main symptom in patients undergoing TEVAR was chest pain (n = 22, 44.7%). The strategy for managing TEVAR with landing zone 2 was to leave the left subclavian artery covered without revascularization. Patients were qualified for each type of procedure (i.e. covered or not covered LSA) due to the aneurysm’s anatomy. When the aneurysm included the aorta directly behind the subclavian artery, there was a need to cover the subclavian artery in order to get a place to attach the stentgraft. In 18 cases LSA was covered without revascularization (35.29%), and 33 remained uncovered (64.71%). The average procedure time was 80.1 min and the average hospital stay was 7.59 days.

Table 1 Demographics and comorbidities of the studied population

| Variable                | Number | %   |
|-------------------------|--------|-----|
| Number of patients      | 51     |     |
| Female sex              | 17     | 33.3|
| Age, years              | 66.6   |     |
| BMI < 25                | 35     | 68.6|
| BMI 25–30               | 5      | 9.8 |
| BMI 30–35               | 11     | 21.5|
| Urgent admission        | 34     | 66.6|
| TEVAR due to aneurysm   | 25     | 49  |
| TEVAR due to acute type B dissection | 26 | 51 |
| Average diameter of aneurysms (cm) | 8.39 | |
| Coexistence of AAA      | 13     | 25.4|
| Tobacco use             | 24     | 47  |
| Hypertension            | 38     | 74.5|
| Coronary artery disease | 13     | 25.4|
| Antiplatelet therapy    | 15     | 29.4|
| Statin therapy          | 17     | 33  |
| Previous stroke         | 6      | 11.7|
| Asymptomatic carotid stenosis | 2 | 3.9 |

Statistical analysis
The analysis of collected data was carried out using TIBCO StatSoft Statistica™ version 13.2 on a computer with the Windows operating system. T-student test and U-Mann-Whitney test were used to compare quantitative data such as mean values, standard deviations or medians. The chi-square test was used to analyse nominal variables, using Yates correction in some cases. The test results for p < 0.05 were considered statistically significant.

Results
In the study population we found no statistically significant differences in the incidence of additional comorbidities such as obesity, ischemic heart disease, hypertension or previous stroke regarding LSA coverage (covered or not covered) (Table 2). In a 30-day observation, 4 patients
(7.84%) experienced ischemic stroke. One patient, who experienced stroke, suffered from carotid artery stenosis. In one patient, the stroke was fatal. The mean age of the patient suffering stroke was 86.57 years. In 3 patients (5.88%) spinal cord ischemia in the form of lower limb paresis occurred after TEVAR. In one of these patients, a number of complications led to his death. Other complications include: reoperation due to hematoma or pseudoaneurysm in the groin (n = 6, 11.7%), arm ischemia requiring surgical intervention (n = 1, 1.96%), wound suppuration (n = 2, 3.92%), delirium (n = 2, 3.92%). Complications are collected in Table 3. In the study population we did not find a statistically significant difference in the incidence of stroke and spinal cord ischemia in patients with covered and uncovered LSA (stroke p = 0.37, SCI p = 0.58). Four out of 33 patients experienced stroke in LSA non covered group and no patient experienced stroke in LSA covered group. When it comes to SCI one out of 18 patients experienced SCI in LSA covered group and 2 out of 33 patients in LSA non-covered group. Although the incidence of neurological complications appears to be greater in non – covered LSA group, it does not reach statistical significance due to the small number of the patients. Number of complications such as myocardial infarction (p = 0.53), or death (p = 0.96) was also not significantly different (Table 4). Patients with neurological complications did not differ in additional comorbidities from patients without neurological complications (Table 5).

### Table 2
Characteristics and comorbidities in patients with covered and non – covered LSA

| Feature                        | LSA covered | LSA non-covered | P     |
|--------------------------------|-------------|-----------------|-------|
| % 18                           | 33          | 51              |       |
| BMI < 25                       | 4           | 8               |       |
| % 22.2%                        | 24.2%       |                 |       |
| BMI25–30                       | 13          | 21              | 0.7826|
| % 72.2%                        | 63.6%       |                 |       |
| BMI > 30                       | 1           | 4               | 0.8458|
| % 5.5%                         | 12.1%       |                 |       |
| Hypertension                   | 12          | 26              | 0.7138|
| % 66.6%                        | 78.7%       |                 |       |
| Previous stroke                | 0           | 6               | 0.1953|
| % 0.0%                         | 18.1%       |                 |       |
| Coronary artery disease        | 2           | 11              | 0.3667|
| % 11.1%                        | 33.3%       |                 |       |
| Urgent admission               | 15          | 19              | 0.4135|
| % 83.3%                        | 57.5%       |                 |       |
| Acute type B dissection        | 12          | 14              | 0.3554|
| % 66.6%                        | 42.4%       |                 |       |
| Aortic aneurism                | 6           | 19              | 0.3197|
| % 33.3%                        | 57.5%       |                 |       |
| Male sex                       | 11          | 23              | 0.7793|
| % 61.1%                        | 69.7%       |                 |       |
| Antiplatelet therapy           | 4           | 11              | 0.7554|
| % 22.2%                        | 33.3%       |                 |       |
| Statin therapy                 | 7           | 10              | 0.6631|
| % 38.8%                        | 30.3%       |                 |       |
| Mean age,years                 | 64.6        | 67.3            | 0.4838|
| % uMW t-student                |             |                 | 0.47439|
| Hospitalization time           | 7.8         | 7.4             | 0.3104|
| % p = 0.7758                   |             |                 | 0.7758|

### Table 3
Complications after TEVAR

| Complications after TEVAR | Number | %  |
|---------------------------|--------|----|
| Ischemic stroke           | 4      | 7.8|
| Spinal cord ischemia      | 3      | 5.8|
| Acute renal failure       | 2      | 3.9|
| Myocardial infarction     | 3      | 5.8|
| Death                     | 4      | 7.8|
| Arm ischemia              | 1      | 1.9|
| Pseudoaneurysm or hematoma in the groin | 6 | 11.7|
| Wound suppuration         | 2      | 3.9|
| Delirium                  | 2      | 3.9|

### Discussion
LSA coverage is necessary to obtain a landing zone in almost one third of the patients qualified for TEVAR [3]. The managing of the LSA (to revascularize or not) is not fully established. Some surgeons routinely perform LSA revascularization. Others selectively, yet another perform LSA revascularization only after symptoms appearance. Whether the LSA coverage is associated with an increased or reduced risk of stroke remains unclear. So far, many studies have been conducted to compare the occurrence of neurological complications after TEVAR in relation to the management of LSA [4–7]. Most of these studies are retrospective ones, low in the strength of scientific evidence, and not randomized clinical trials.

In the meta-analysis taking into account researches from 1990 to 2008, it was found that the LSA coverage is associated with an increased risk of arm ischaemia and CNS ischaemia in the vertebral - basilar circulation [4]. However, this was not associated with an increase risk of spinal cord ischaemia. In this study, no correlation was found between LSA coverage and higher risk of death, myocardial infarction or TIA. Evidence for this, however, is also weak, based mainly on retrospective studies.

The authors of the 2014 paper, who analysed 1010 patients after TEVAR in 2002–2010 also have similar
views. They found that patients with LSA coverage are more likely to have ischemic stroke ($p < 0.01$), especially in posterior territory, and this is an important risk factor in patients undergoing TEVAR [5].

In a subsequent study of 1189 patients, the LSA coverage was found not to be associated with an increased risk of SCI or CVA [6]. There was no difference in SCI and CVA rates among patients undergoing LSA coverage with or without revascularization (SCI, 6.3% vs 6.1%, CVA, 6.7% vs 6.1%).

The authors of this work are opposed to the SVS recommendations. In 2009 r. SVS based on the analysis of 51 studies found that routine LSA revascularization is associated with a reduced number of neurological complications (stroke and spinal cord ischemia) [7]. Therefore, according to the guidelines, the Grade 2 Level C recommendation is to routinely revascularize LSA. Evidence for this are derived from mainly retrospective studies with low-quality scientific evidence rather than randomized clinical trials. In our study, we did not find a statistically significant difference in the incidence of neurological complications in patients with LSA coverage compared to patients with an uncovered LSA. However, the limitation of this study is the fact that a small group was analysed ($n = 51$).

It is now believed that the cause of stroke and SCI after TEVAR is multifactorial. One of the important elements causing the stroke is intraoperative embolism from the atherosclerotic plaques of the aortic arch, another reduction in the flow through the vertebral arteries [3, 8]. The reason for SCI is the covering of the intercostal arteries (mainly Th 9–12), Adamkiewicz’s artery, LSA and previous abdominal aortic aneurysm surgery [9–11].

Although TEVAR is associated with a reduced risk of neurological complications comparing to an open surgery, the risk is still high. In the recommendations for the descending aortic pathology issued by ESVS, the Class II level C recommendation is revascularization of covered LSA, but only in selected patients with an increased risk of neurological complications [3]. The authors state that this should be done in the case of the dominant left subclavian artery, after the left internal

| Feature                  | LSA covered | LSA non-covered | P    |
|--------------------------|-------------|-----------------|------|
| Stroke                   | 0           | 4               | 0.3706 |
| %                        | 0%          | 12.1%           |      |
| SCI                      | 1           | 2               | 0.5803 |
| %                        | 5.5%        | 6%              |      |
| ARF                      | 1           | 1               | 0.7443 |
| %                        | 5.5%        | 3%              |      |
| Cardiac arrest           | 1           | 1               | 0.7443 |
| %                        | 5.5%        | 3%              |      |
| Death                    | 2           | 2               | 0.9609 |
| %                        | 11.1%       | 6%              |      |
| MI                       | 0           | 3               | 0.5286 |
| %                        | 0%          | 9%              |      |
| Neurological complications in total | 1          | 6               | 0.4958 |
| %                        | 5.5%        | 18.1%           |      |

| Feature                  | Neurological complication | Without neurological complication |
|--------------------------|---------------------------|----------------------------------|
| AGE <=70                 | 3                         | 27                               |
| > 70                     | 4                         | 17                               |
| BMI < 25                 | 7                         | 29                               |
| 25–30                    | 7                         | 27                               |
| > 30                     | 0                         | 15                               |
| Hypertension yes         | 5                         | 33                               |
| no                       | 2                         | 11                               |
| Previous stroke yes      | 1                         | 5                                |
| no                       | 6                         | 39                               |
| Coronary artery disease yes | 1                       | 12                               |
| no                       | 6                         | 32                               |
| Urgent admission yes     | 4                         | 30                               |
| no                       | 3                         | 14                               |
| Aortic aneurism –        | 1                         | 24                               |
| Acute type B dissection – | 6                         | 20                               |
| Mean age, years          | 70.2                      | 66.7                             |
| Average hospital stay    | 10.1                      | 7.8                              |

Janczak et al. Journal of Cardiothoracic Surgery (2019) 14:5 Page 4 of 6
In our study, we did not find statistically significant differences in the incidence of neurological complications in patients with covered and uncovered LSA. Although there are many studies analysing the risk of such complications, there is no specific consensus regarding the treatment of LSA-covered. Randomized clinical trials on a large group of patients are still needed.

Conclusions

Abbreviations

BMI: Body mass index; CNS: Central nervous system; CVA: Cerebrovascular accident; ESVS: European Society for Vascular Surgery; LSA: Left subclavian artery; SCI: Spinal cord ischemia; TEVAR: Thoracic endovascular aortic repair; TIA: Transient ischemic attack; TIBCO: The Information Bus Company

Acknowledgements

Not applicable.

Funding

The authors declare that they have received no external funding for this study.

Availability of data and materials

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

DJ participated in the design of the study and helped to draft the manuscript. A2Z interpreted the data and participated in the design of the study. JK critically revised the manuscript for important intellectual content. MM conceived of the study and arranged the manuscript. KP participated in the design of the study and interpreted the data. MC participated in the design of the paper and wrote the manuscript and collected the data. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

This original paper was approved by the local ethics committee of Wroclaw Medical University. All participants consented to participate in the study and the written informed consent was obtained from each subject.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Department of Vascular, General and Transplantation Surgery, Faculty of Postgraduate Medical Training, Wroclaw Medical University, 213 Borowska street, 50-556, Wroclaw, Poland. 2Department of Surgery, 4th Military Teaching Hospital, 5 Weigla street, 50-981, Wroclaw, Poland. 3Division of Surgical Specialties, Department of Clinical Nursing, Faculty of Health Science, Wroclaw Medical University, 5 Bartla Street, 51-618, Wroclaw, Poland.

Received: 17 October 2018 Accepted: 26 December 2018

Published online: 08 January 2019

References

1. Makaroun MS, Dillavou ED, Kee ST, et al. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis. J Vasc Surg. 2005;41:1–9.
2. Patterson B, Holt P, Nienaber C, Cambria R, Fairman R, Thompson M. Aortic pathology determines midterm outcome after endovascular repair of the thoracic aorta: report from the Medtronic thoracic endovascular registry (MOTHER) database. Circulation. 2013;127:24–32.
3. Riambau V, Böckler D, Brunkwall J, et al. Management of Descending Thoracic Aorta Diseases Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg. 2017;53:4–52.
4. Rizvi AZ, Murad MH, Fairman RM, Erwin PJ, Montori VM. The effect of left subclavian artery coverage on morbidity and mortality in patients undergoing endovascular thoracic aortic interventions: a systematic review and meta-analysis. J Vasc Surg. 2009;50:1159–69.
5. Patterson BO, Holt PJ, Nienaber C, Fairman RM, Heijnen RH, Thompson MW. Management of the left subclavian artery and neurologic complications after thoracic endovascular aortic repair. J Vasc Surg. 2014;60:1491–7.
6. Maldonado TS, Dexter D, Rockman CB, et al. Left subclavian artery coverage during thoracic endovascular aortic aneurysm repair does not mandate revascularization. J Vasc Surg. 2013;57:116–24.
7. Matsumura JS, Lee WA, Mitchell RS, et al. The Society for Vascular Surgery Practice Guidelines: management of the left subclavian artery with thoracic endovascular aortic repair. J Vasc Surg. 2009;50:1155–8.
8. Khoynezhad A, Donayre C, Bui H, Kopchok GE, Walcot I, White RA. Risk factors of neurologic deficit after thoracic aortic Endografting. Ann Thorac Surg. 2007;83:882–9.
9. Amabile P, Grisoli D, Giorgi R, Bartoli JM, Piquet P. Incidence and determinants of spinal cord ischemia in stent-graft repair of the thoracic aorta. Eur J Vasc Endovasc Surg. 2008;35:455–61.
10. Sueda T, Takahashi S. Spinal cord injury as a complication of thoracic endovascular aneurysm repair. Surg Today. 2018;48(5):473–7.

11. Buth J, Harris PL, Hobo R, van Eps R, Cuypers P, Duijm L, Tielbeek X. Neurologic complications associated with endovascular repair of thoracic aortic pathology: incidence and risk factors. A study from the European collaborators on stent/graft techniques for aortic aneurysm repair (EUROSTAR) registry. J Vasc Surg. 2007;46:1103–10.